Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple blood test could spot 20 cancers before symptoms start

NCT ID NCT05366881

Diagnosis Sponsor: Adela, Inc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a blood test that looks for DNA signals from 20 different cancers, including lung, breast, and colon cancer. Researchers will see if the test can find cancer early, detect any cancer left after treatment, and catch a relapse before it shows up on scans. The study involves 7,000 adults aged 40 and older who are either newly diagnosed with cancer or have no cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 7,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2022

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will enroll individuals with newly diagnosed cancer as cancer cases and individuals without known cancer as controls. Participants will be enrolled from sites across the United States.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Case Inclusion Criteria: * Newly diagnosed (within 120 days) with cancer or a recurrence of a cancer diagnosed \>5 years ago of one of the following subtypes: Invasive Brain, Breast, Bladder, Cervical, Colorectal, Endometrial, Esophageal, Gastric, Head and Neck, Hepatobiliary, Lung, Ovarian, Pancreatic, Prostate, Renal, Sarcoma, Thyroid; Leukemia, Lymphoma, Multiple Myeloma * Able and willing to provide informed consent * ≥40 years of age Case Exclusion Criteria: * Currently receiving any treatment for cancer * Currently taking any demethylating agents/DNA hypomethylating agents * Simultaneously diagnosed with two or more invasive cancers * Diagnosed with any invasive or non-invasive cancer in addition to the index cancer in the last 5 years * Currently diagnosed with any chronic hematopoietic cancer (e.g. chronic CLL) in addition to the index cancer * Currently diagnosed with any myelodysplastic syndromes and/or precursor hematologic conditions (e.g. MGUS) in addition to the index cancer * Women who are known to be pregnant (self-reported) Control Inclusion Criteria * Not diagnosed with any cancer in the last 5 years (non-invasive cancer is allowed) * Able and willing to provide informed consent * ≥40 years of age Control Exclusion Criteria * Currently receiving any treatment for cancer * Currently taking any demethylating agents/DNA hypomethylating agents * Women who are known to be pregnant (self-reported)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bladder cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer breast cancer breast neoplasm cervical cancer colorectal cancer colorectal neoplasm endometrial cancer endometrium neoplasm esophageal cancer Esophageal Neoplasms gastric cancer gastric neoplasm head and neck cancer Head and Neck Neoplasms hepatobiliary neoplasm kidney cancer leukemia lung cancer lung neoplasm lymphoma malignant pancreatic neoplasm ovarian cancer pancreatic neoplasm plasma cell myeloma prostate cancer renal carcinoma sarcoma thyroid cancer Thyroid Neoplasms urinary bladder carcinoma Urinary Bladder Neoplasms Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bladder cancer Brain cancer Breast cancer Cervical cancer Colorectal cancer Endometrial cancer Esophageal cancer Head and neck cancer Hepatobiliary cancer Leukemia Lung cancer Lymphoma Multiple myeloma Ovarian cancer Pancreatic cancer Prostate cancer Renal cancer Sarcoma Stomach cancer Thyroid cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    16 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Allina Health Cancer Institute

    RECRUITING

    Minneapolis, Minnesota, 55407, United States

  • Baptist (BHMCC)

    RECRUITING

    Memphis, Tennessee, 38120, United States

  • Baptist Corbin

    RECRUITING

    Corbin, Kentucky, 40701, United States

  • Baptist Floyd

    RECRUITING

    New Albany, Indiana, 47150, United States

  • Baptist Hardin

    RECRUITING

    Elizabethtown, Kentucky, 42701, United States

  • Baptist Lexington

    RECRUITING

    Lexington, Kentucky, 40503, United States

  • Baptist Paducah

    WITHDRAWN

    Paducah, Kentucky, 42003, United States

  • City of Hope

    RECRUITING

    Duarte, California, 91010, United States

  • Cleveland Clinic

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • Elligo Health Research, Inc.

    RECRUITING

    Austin, Texas, 78704, United States

  • Mayo Clinic

    RECRUITING

    Rochester, Minnesota, 55902, United States

  • McLeod Health

    RECRUITING

    Florence, South Carolina, 29502, United States

  • Medical University of South Carolina

    RECRUITING

    Charleston, South Carolina, 29425, United States

  • Miami Cancer Institute

    RECRUITING

    Miami, Florida, 33176, United States

  • North Georgia Health System

    RECRUITING

    Gainesville, Georgia, 306501, United States

  • Oregon Health Sciences University

    RECRUITING

    Portland, Oregon, 97201, United States

  • Vanderbilt-Ingram Cancer Center

    RECRUITING

    Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.